As of 2024-12-12, the EV/EBITDA ratio of Intra-Cellular Therapies Inc (ITCI) is -69.61. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ITCI's latest enterprise value is 8,428.65 mil USD. ITCI's TTM EBITDA according to its financial statements is -121.08 mil USD. Dividing these 2 quantities gives us the above ITCI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.7x - 10.9x | 10.0x |
| Forward P/E multiples | 16.7x - 20.3x | 19.2x |
| Fair Price | (14.72) - (8.07) | (12.29) |
| Upside | -117.5% - -109.6% | -114.7% |
| Date | EV/EBITDA |
| 2024-12-06 | -70.20 |
| 2024-12-05 | -69.79 |
| 2024-12-04 | -71.42 |
| 2024-12-03 | -70.86 |
| 2024-12-02 | -71.49 |
| 2024-11-29 | -71.16 |
| 2024-11-27 | -71.98 |
| 2024-11-26 | -71.84 |
| 2024-11-25 | -70.58 |
| 2024-11-22 | -71.19 |
| 2024-11-21 | -70.98 |
| 2024-11-20 | -71.15 |
| 2024-11-19 | -69.15 |
| 2024-11-18 | -68.38 |
| 2024-11-15 | -69.21 |
| 2024-11-14 | -72.89 |
| 2024-11-13 | -73.41 |
| 2024-11-12 | -73.65 |
| 2024-11-11 | -76.34 |
| 2024-11-08 | -76.10 |
| 2024-11-07 | -75.42 |
| 2024-11-06 | -74.48 |
| 2024-11-05 | -74.30 |
| 2024-11-04 | -71.62 |
| 2024-11-01 | -71.94 |
| 2024-10-31 | -70.37 |
| 2024-10-30 | -71.00 |
| 2024-10-29 | -63.37 |
| 2024-10-28 | -63.43 |
| 2024-10-25 | -62.54 |
| 2024-10-24 | -62.40 |
| 2024-10-23 | -61.85 |
| 2024-10-22 | -63.66 |
| 2024-10-21 | -63.51 |
| 2024-10-18 | -64.76 |
| 2024-10-17 | -65.06 |
| 2024-10-16 | -62.79 |
| 2024-10-15 | -61.58 |
| 2024-10-14 | -60.82 |
| 2024-10-11 | -62.50 |
| 2024-10-10 | -60.62 |
| 2024-10-09 | -60.29 |
| 2024-10-08 | -59.55 |
| 2024-10-07 | -58.50 |
| 2024-10-04 | -59.99 |
| 2024-10-03 | -59.43 |
| 2024-10-02 | -59.75 |
| 2024-10-01 | -59.78 |
| 2024-09-30 | -60.23 |
| 2024-09-27 | -60.35 |